News

Clinical Trials Arena35m

60 Degrees to commence Phase II babesiosis trial at Mount Sinai

Degrees Pharmaceuticals has entered into a clinical study agreement with the Icahn School of Medicine at Mount Sinai in the ...
The Manila Times1h

I-Mab Reports Second Quarter 2025 Financial Results and Provides Business Update

Positive givastomig Phase 1b dose escalation data in combination with immunochemotherapy in patients with 1L gastric cancers ...

AlzeCure Pharma: AlzeCure Appoints Cecilia Wadell as New Head of Development

STOCKHOLM, SE / ACCESS Newswire / August 20, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusin ...

Viking Therapeutics: Phase 2 Oral Obesity Data Affirms Bear Case, Downgrade To Sell

Viking Therapeutics, Inc.'s obesity drug VK2735 results reveal no clear edge over leading competitors. Click for why this ...
The Manila Times15h

Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE)

Study met primary endpoint demonstrating barzolvolimab’s ability to potently deplete mast cells in the gastrointestinal ...
Applied Clinical Trials Online17h

Phase II Trial Demonstrates Encouraging Anti-Tumor Activity in Non-Small Cell Lung Cancer with sac-TMT

Results from the Phase II OptiTROP-Lung01 trial (NCT05351788) showed that Sichuan Kelun-Biotech’s sac-TMT combined with ...

MIRA Pharmaceuticals Announces Completion of Phase 1 Single Ascending Dose for Oral Ketamir-2 with No Safety Concerns, Advances to Multiple Ascending Dose Stage

Following FDA IND clearance for neuropathic pain, the Company is preparing to initiate its U.S. Phase 2a trial in Q4 2025 MIAMI, FL / ACCESS Newswire / August 19, 2025 / MIRA Pharmaceuticals, Inc. (NA ...